efs-ada transduced cd34+ bone marrow cells
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01852071)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- efs-ada transduced cd34+ bone marrow cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01852071 | Phase 1/Phase 2 (Phase 2) | May 1, 2013 | National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2013 |
| National Human Genome Research Institute (NHGRI) | Government | 1 | 0 | 1 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2013 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2013 |
4 organizations
Page 1 / 1